Vir Biotechnology Files 8-K

Ticker: VIR · Form: 8-K · Filed: 2025-07-24T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

TL;DR

Vir Bio filed an 8-K on 7/24 - check for updates.

AI Summary

Vir Biotechnology, Inc. filed an 8-K on July 24, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about new events or financial figures, but serves as a notification of these items being filed.

Why It Matters

This 8-K filing indicates that Vir Biotechnology has submitted important updates or disclosures to the SEC, which could include significant business events or financial information.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure without immediate negative or positive financial implications detailed within the provided text.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Vir Biotechnology, Inc. in this 8-K filing?

The provided text for the 8-K filing lists 'Other Events' as an item information category but does not specify the nature of these events.

What financial statements or exhibits are being filed with this 8-K?

The filing indicates that 'Financial Statements and Exhibits' are being filed, but the specific contents are not detailed in the provided text.

When was this 8-K filing submitted to the SEC?

The filing was submitted on July 24, 2025, as indicated by the 'CONFORMED SUBMISSION TYPE' and 'FILED AS OF DATE'.

What is the principal executive office address for Vir Biotechnology, Inc.?

The principal executive offices are located at 1800 Owens Street, Suite 900, San Francisco, California 94158.

What is the IRS Employer Identification Number (EIN) for Vir Biotechnology, Inc.?

The IRS Employer Identification Number for Vir Biotechnology, Inc. is 81-2730369.

From the Filing

0001628280-25-035847.txt : 20250724 0001628280-25-035847.hdr.sgml : 20250724 20250724090539 ACCESSION NUMBER: 0001628280-25-035847 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250724 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250724 DATE AS OF CHANGE: 20250724 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 251144724 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 8-K 1 vir-20250724.htm 8-K vir-20250724 FALSE 0001706431 0001706431 2025-07-24 2025-07-24 0001706431 exch:XNAS 2025-07-24 2025-07-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 ________________________________________ Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) ________________________________________ Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1800 Owens Street , Suite 900 San Francisco , California 94158 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: ( 415 ) 906-4324 (Former Name or Former Address, if Changed Since Last Report) ________________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.0001 par value VIR Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 8.01 Other Events. On July 24, 2025, Vir Biotechnology, Inc. (the Company) issued a press release announcing the first patient dosed in the Company’s Phase 1 clinical trial evaluating VIR-5525, an investigational dual-masked T-cell engager targeting EGFR (epidermal growth factor receptor). A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated July 24, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of

View on Read The Filing